Synthesis, Anti-Proliferative Evaluation and Mechanism of 4-Trifluoro Methoxy Proguanil Derivatives with Various Carbon Chain Length

• Published in: Molecules (Basel, Switzerland) Vol. 26; no. 19; p. 5775
• Main Authors: Xu, Simeng, Cao, Yufang, Luo, Yu, Xiao, Di, Wang, Wei, Wang, Zhiren, Yang, Xiaoping
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 24.09.2021; MDPI
• Subjects: AMPK; anti-cancer; Antiproliferatives; biguanide; Biological activity; Bladder cancer; Cancer; Carbon; Cell growth; Cloning; Colonies; Diabetes; FDA approval; Fluorine; Inactivation; Kinases; Metabolism; Molecular chains; NMR; Nuclear magnetic resonance; Ovarian cancer; Proguanil; TOR protein; trifluoromethoxy; Tuberculosis; Tumor cell lines; Vacuum distillation; United States > US
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules26195775

Among the known biguanide drugs, proguanil has the best antiproliferative activity. In contrast, newly synthesized biguanide derivatives containing fluorine atoms have excellent biological activity, among which trifluoromethoxy compounds show the strongest ability. Preliminary work in our laboratory exhibited that n-heptyl containing proguanil derivatives on one alkyl chain side have better biological activity than those with a shorter carbon chain. However, the relationship between the length of the carbon chain and the activity of the compounds is unknown. In this study, we synthesized 10 new trifluoromethoxy-containing proguanil derivatives with various carbon chain lengths. The phenyl side is fixed as the trifluoromethoxy group with change of carbon chain length in alkyl chain side. It was found that the anti-cancer abilities of 5C–8C with n-pentyl to n-octyl groups was significantly better than that of proguanil in the five human cancer cell lines. The colony formation assay demonstrated that 6C–8C at 0.5 to 1.0 μM significantly inhibited the colony formation of human cancer cell lines, much stronger than that of proguanil. Pharmacologically, 8C activates AMPK, leading to inactivation of the mTOR/p70S6K/4EBP1 pathway. Thus, these novel compounds have a great potential for developing new anti-cancer candidates.